



## FY 20 FDA Final BA Appropriations, Compared with FY 19 Funding

ANALYSIS as of December 18, 2019—Subject to change.

*Some columns may not add due to rounding*

Budget Line—BA only “Salary and Expenses”	FY 19	House-FY 20	Senate--FY20	FY 20 Final	FY 20 Final compared to FY 19
Food	\$ 1.060 billion	\$ 1.101 billion	\$1.081 billion	\$1.089 billion	+ \$ 29 million
Human Drugs	\$ 663 million	\$ 713 million	\$ 678 million	\$ 683 million	+ \$ 20 million
Biologics	\$ 240 million	\$ 262 million	\$ 252 million	\$ 252 million	+ \$ 12 million
Animal Drugs and Feeds	\$ 179 million	\$ 196 million	\$ 194 million	\$ 191 million	+ \$ 12 million
Devices/Rad Health	\$ 387 million	\$ 420 million	\$ 394 million	\$ 395 million	+ \$ 8 million
National Center Tox. Research	\$ 67 million	\$ 67 million	\$ 67 million	\$ 67 million	No change
Office of the Commissioner	\$ 188 million	\$ 192 million	\$ 182 million	\$ 185 million	- \$ 3 million
All rent items; WO consolidation	\$ 285 million	\$ 303 million	\$ 300 million	\$ 297 million	+ \$ 12 million
<b>Budget Authority Total</b>	<b>\$ 3.069 billion</b>	<b>\$ 3.254 billion</b>	<b>\$3.148 billion</b>	<b>\$3.160 billion</b>	<b>+ \$ 91 million (~3%)</b>

**Medical Product increases distributed within the chart (~\$48.9 million):** \$7 million for medical countermeasures; \$10 million for pathogen reduction in the blood supply; \$1 million for lab safety; \$9 million for compounding; \$4 million for medical device safety/cyber security; \$2 million for medtech manufacturing; \$1.9 million for generic drugs; \$8 million for opioids; \$5 million for rare cancer therapeutics; and \$1 million for the pediatric device consortium.

**Food Safety increases distributed with the chart (~\$31.5 million):** \$5 million for innovation and emerging technology; \$7 million for advancing FSMA; \$8 million for strengthening response to foodborne outbreaks; \$3 million for dietary supplements; \$5 million for imported seafood safety; \$2 million for CBD activities; \$500,000 for antimicrobial monitoring system; \$1 million for standards of identity.

**Critical Infrastructure Improvements distributed within the chart (\$12.1 million)** for critical infrastructure improvements. This is partial fulfillment of a \$31 million budget request for infrastructure improvements at White Oak and in the two rent payment budget accounts.

**Buildings and Facilities.** For FY 20, FDA has received \$11.79 million for “Buildings and Facilities.” Congress added **\$20 million of “no-year” monies for equipment and facilities used for FDA seafood safety activities.** This will expand research labs and address deferred maintenance.

**21<sup>st</sup> Century Cures/FDA Innovation Fund monies** come from reductions in mandated spending; not included in BA appropriations totals.

For more information, contact Steven Grossman, the Alliance’s Deputy Executive Director: [sgrossman@strengthenfda.org](mailto:sgrossman@strengthenfda.org) or 301-539-9660